TED-A9

TED-A9 is an investigational allogeneic cell therapy consisting of highly purified ventral midbrain-specific dopaminergic progenitor cells derived from human embryonic stem cells (hESCs). The therapy is designed to replace the dopaminergic neurons lost in patients with Parkinson’s disease. These precursor cells are generated using small molecules and are surgically transplanted into three segments of the putamen in the brain. Once transplanted, they are expected to mature into functional dopaminergic neurons that restore dopamine levels and improve motor function. Clinical trials have shown improvements in motor symptoms such as wearing-off and freezing of gait, with imaging studies confirming engraftment through increased dopamine transporter expression. TED-A9 represents a significant advancement as a potential disease-modifying treatment for Parkinson’s disease by directly replacing lost neurons[1][3][4][5][6].

Other names

Allogenic embryonic stem cell-derived A9 dopamine progenitor cell therapy